Replies to post #158972 on Biotech Values

[dav1234]

Ariad Pharmaceuticals (ARIA -0.8%) gets only a tentative nod from Goldman Sachs today, after the company initiated the shares with a Neutral rating, saying the stock is fairly valued at current levels. Goldman notes that since its launching of Iclusig last December, the stock has already appreciated 55%, and trades at a healthy premium to both its cancer peers and the broader S&P 500 index